{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:11:34Z","timestamp":1789679494955,"version":"4.0.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rapid Service and Open Access"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>PsA is a heterogeneous disease that impacts many aspects of social and mental life, including quality of life. Risankizumab, an antagonist specific for IL-23, is currently under investigation for the treatment of adults with active PsA. This study evaluated the impact of risankizumab vs placebo on health-related quality of life (HRQoL) and other patient-reported outcomes (PROs) among patients with active PsA and inadequate response or intolerance to conventional synthetic DMARD (csDMARD-IR) in the KEEPsAKE 1 trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adult patients with active PsA (n\u2009=\u2009964) were randomized (1:1) to receive risankizumab 150\u2009mg or placebo. PROs assessed included the 36-Item Short-Form Health Survey (SF-36, v2), Functional Assessment of Chronic Illness Therapy\u2013Fatigue (FACIT-Fatigue), EuroQoL-5 Dimension-5 Level (EQ-5D-5L), Patient\u2019s Assessment of Pain, Patient\u2019s Global Assessment (PtGA) of Disease Activity, and Work Productivity and Activity Impairment\u2013PsA (WPAI-PsA) questionnaire. Least squares (LS) mean change from baseline at week 24 was compared between risankizumab and placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At week 24, differences between groups were observed using LS mean changes from baseline in SF-36 physical component summary and mental component summary; FACIT-Fatigue; EQ-5D-5L; Patient\u2019s Assessment of Pain; PtGA; all eight SF-36 domains (all nominal P\u2009&amp;lt;\u20090.001); and the WPAI-PsA domains of impairment while working (presenteeism), overall work impairment and activity impairment (all nominal P\u2009&amp;lt;\u20090.01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Risankizumab treatment resulted in greater improvements in HRQoL, fatigue, pain and work productivity in patients with active PsA who have csDMARD-IR, when compared with placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov, https:\/\/clinicaltrials.gov, NCT03675308<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac342","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T13:18:19Z","timestamp":1657286299000},"page":"629-637","source":"Crossref","is-referenced-by-count":12,"title":["Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0686-7102","authenticated-orcid":false,"given":"Lars Erik","family":"Kristensen","sequence":"first","affiliation":[{"name":"The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M","family":"Soliman","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Papp","sequence":"additional","affiliation":[{"name":"K Papp Clinical Research and Probity Medical Research , Waterloo, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"White","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Waikato Hospital , Hamilton"},{"name":"Waikato Clinical School, University of Auckland , Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Barcomb","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Lu","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Eldred","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[{"name":"Rheumatology, Fraunhofer Institute Translational Medicine and Pharmacology ITMP & Cluster of Excellence CIMD, Goethe University , Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"2023020117302214000_keac342-B1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.berh.2012.01.003","article-title":"Psoriatic arthritis [review]","volume":"26","author":"Duarte","year":"2012","journal-title":". Best Pract Res Clin Rheumatol"},{"key":"2023020117302214000_keac342-B2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/keq262","article-title":"Observational cohort studies: lessons learnt from the University of Toronto psoriatic arthritis program [review]","volume":"50","author":"Gladman","year":"2011","journal-title":". Rheumatology"},{"key":"2023020117302214000_keac342-B3","first-page":"680","article-title":"The burden of psoriatic arthritis: a literature review from a global health systems perspective","volume":"35","author":"Lee","year":"2010","journal-title":"Pharm Ther"},{"key":"2023020117302214000_keac342-B4","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1136\/annrheumdis-2012-202229","article-title":"Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study","volume":"72","author":"Kristensen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2023020117302214000_keac342-B5","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/annrheumdis-2016-210579","article-title":"Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study","volume":"76","author":"Kristensen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023020117302214000_keac342-B6","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2011-200387","article-title":"Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment","volume":"71","author":"Strand","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2023020117302214000_keac342-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-7-25","article-title":"The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people","volume":"7","author":"Salaffi","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"2023020117302214000_keac342-B8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis [review]","volume":"14","author":"Gudu","year":"2018","journal-title":". Expert Rev Clin Immunol"},{"key":"2023020117302214000_keac342-B9","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis [review]","volume":"59","author":"Ogdie","year":"2020","journal-title":". Rheumatology"},{"key":"2023020117302214000_keac342-B10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023020117302214000_keac342-B11","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keab119","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology"},{"key":"2023020117302214000_keac342-B12","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3021","article-title":"Remission in psoriatic arthritis: is it possible and how can it be predicted?","volume":"12","author":"Saber","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2023020117302214000_keac342-B13","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3899\/jrheum.150805","article-title":"Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-\u03b1 drugs","volume":"43","author":"Perrotta","year":"2016","journal-title":"J Rheumatol"},{"key":"2023020117302214000_keac342-B14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3899\/jrheum.170449","article-title":"Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature [review]","volume":"45","author":"Gossec","year":"2018","journal-title":". J Rheumatol"},{"key":"2023020117302214000_keac342-B15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-065X.2008.00699.x","article-title":"The roles of IL-17A in inflammatory immune responses and host defense against pathogens [review]","volume":"226","author":"Iwakura","year":"2008","journal-title":"Immunol Rev"},{"key":"2023020117302214000_keac342-B16","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamadermatol.2020.3617","article-title":"Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials","volume":"156","author":"Augustin","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2023020117302214000_keac342-B17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2023020117302214000_keac342-B18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"2023020117302214000_keac342-B19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 keepsake 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023020117302214000_keac342-B20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 keepsake 2 trial","volume":"81","author":"\u00d6st\u00f6r","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023020117302214000_keac342-B21","first-page":"200","article-title":"Op0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023020117302214000_keac342-B22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2023020117302214000_keac342-B23","volume-title":"SF-36 physical and mental health summary scales: a user's manual","author":"Ware","year":"1994"},{"key":"2023020117302214000_keac342-B24","volume-title":"SF-36. Health survey: manual and interpretation guide","author":"Ware","year":"1993"},{"key":"2023020117302214000_keac342-B25","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/ard.2006.065763","article-title":"Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis","volume":"66","author":"Chandran","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023020117302214000_keac342-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12955-015-0361-y","article-title":"Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores?","volume":"13","author":"Luo","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"2023020117302214000_keac342-B27","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"2023020117302214000_keac342-B28","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1002\/acr.20543","article-title":"Measures of adult pain: visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), McGill pain questionnaire (MPQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (icoap) [review]","volume":"63","author":"Hawker","year":"2011","journal-title":". Arthritis Care Res"},{"key":"2023020117302214000_keac342-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-016-1151-6","article-title":"Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature [review]","volume":"18","author":"Nikiphorou","year":"2016","journal-title":". Arthritis Res Ther"},{"key":"2023020117302214000_keac342-B30","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"2023020117302214000_keac342-B31","author":"Reilly Associates"},{"key":"2023020117302214000_keac342-B32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"2023020117302214000_keac342-B33","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s40744-021-00379-9","article-title":"Improvement in patient-reported outcomes in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: results from select-PSA 1","volume":"8","author":"Strand","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2023020117302214000_keac342-B34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3899\/jrheum.170150","article-title":"Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT working group","volume":"44","author":"Ogdie","year":"2017","journal-title":"J Rheumatol"},{"key":"2023020117302214000_keac342-B35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.41553","article-title":"Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis","volume":"73","author":"McInnes","year":"2021","journal-title":"Arthritis Rheum"},{"key":"2023020117302214000_keac342-B36","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2023020117302214000_keac342-B37","doi-asserted-by":"crossref","first-page":"e001321","DOI":"10.1136\/rmdopen-2020-001321","article-title":"Patient\u2019s experience of psoriatic arthritis: a conceptual model based on qualitative interviews","volume":"6","author":"Ogdie","year":"2020","journal-title":"RMD open"},{"key":"2023020117302214000_keac342-B38","first-page":"566","article-title":"Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-p2 results to 52 weeks","volume":"37","author":"Kavanaugh","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2023020117302214000_keac342-B39","doi-asserted-by":"crossref","first-page":"e000808","DOI":"10.1136\/rmdopen-2018-000808","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"2023020117302214000_keac342-B40","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/annrheumdis-2018-215003","article-title":"The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies","volume":"78","author":"Kavanaugh","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac342\/44819418\/keac342.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/2\/629\/49031586\/keac342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/2\/629\/49031586\/keac342.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:40:14Z","timestamp":1675298414000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/2\/629\/6633944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,7,8]]},"published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac342","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,7,8]]}}}